We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+8.9%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$125M
Cap. Flow
+$100M
Cap. Flow %
7.26%
Top 10 Hldgs %
41.14%
Holding
237
New
73
Increased
38
Reduced
39
Closed
63

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$12.5M
2
ETNB
89bio
ETNB
+$10.8M
3
IMTX icon
Immatics
IMTX
+$6.72M
4
BMY icon
Bristol-Myers Squibb
BMY
+$6.02M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$5.91M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$15.7M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$12.5M
3
KURA icon
Kura Oncology
KURA
+$10.1M
4
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$9.46M
5
ZGNX
Zogenix, Inc.
ZGNX
+$7.96M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
176
DELISTED
Allakos
ALLK
– –
-42,536
Closed -$3.06M
ARGX icon
177
argenx
ARGX
$53.4B
– –
-1,750
Closed -$421K
ARVN icon
178
PUT
Arvinas
ARVN
$518M
– –
-154,000
Closed -$5.17M
AUPH icon
179
Aurinia Pharmaceuticals
AUPH
$1.91B
– –
-327,771
Closed -$4.75M
AXSM icon
180
CALL
Axsome Therapeutics
AXSM
$11.2B
– –
-18,300
Closed -$1.51M
BBIO icon
181
CALL
BridgeBio Pharma
BBIO
$15.7B
– –
-31,500
Closed -$1.03M
BLUE
182
CALL
DELISTED
bluebird bio
BLUE
– –
-2,702
Closed -$2.14M
BMRN icon
183
CALL
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-37,700
Closed -$4.65M
BPMC
184
CALL
DELISTED
Blueprint Medicines
BPMC
– –
-128,400
Closed -$10M
BPMC
185
DELISTED
Blueprint Medicines
BPMC
– –
-201,662
Closed -$15.7M
BPMC
186
PUT
DELISTED
Blueprint Medicines
BPMC
– –
-400,000
Closed -$31.2M
CLLS
187
Cellectis
CLLS
$277M
– –
-73,067
Closed -$1.3M
CRBP icon
188
PUT
Corbus Pharmaceuticals
CRBP
$166M
– –
-45,000
Closed -$11.3M
CVM icon
189
PUT
CEL-SCI Corp
CVM
$20.3M
– –
-21,257
Closed -$9.51M
DNTH icon
190
Dianthus Therapeutics
DNTH
$5.84B
– –
-542
Closed -$65K
FXI icon
191
PUT
iShares China Large-Cap ETF
FXI
$4.37B
– –
-600,000
Closed -$23.8M
GILD icon
192
Gilead Sciences
GILD
$162B
– –
-6,218
Closed -$478K
GNFT
193
DELISTED
Genfit
GNFT
– –
-64,027
Closed -$353K
INCY icon
194
Incyte
INCY
$24.2B
– –
-3,700
Closed -$357K
INSM icon
195
Insmed
INSM
$21.4B
– –
-2,919
Closed -$80K
IWM icon
196
iShares Russell 2000 ETF
IWM
$79.8B
– –
-1,154
Closed -$165K
LEGN icon
197
Legend Biotech
LEGN
$3.59B
– –
-5,000
Closed -$213K
MCRB icon
198
PUT
Seres Therapeutics
MCRB
$46.8M
– –
-17,615
Closed -$1.68M
MRNA icon
199
CALL
Moderna
MRNA
$21.8B
– –
-30,000
Closed -$1.93M
NERV icon
200
CALL
Minerva Neurosciences
NERV
$185M
– –
-80,200
Closed -$2.32M
6 7
8
9 10

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Ikarian Capital held 237 positions worth $1.38B, up 10% from $1.26B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital deployed $100M of net new capital in Q3 2020, opening 73 new positions and adding to 38 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier.

On the sell side, the largest reduction was BioXcel Therapeutics, an estimated $12.5M trimmed.

  • Ikarian Capital's largest Q3 2020 buy was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.
  • Ikarian Capital added most to Kiniksa Pharmaceuticals in Q3 2020, an estimated $5.91M increase.
  • Ikarian Capital's biggest Q3 2020 reduction was BioXcel Therapeutics, cutting an estimated $12.5M.
  • Ikarian Capital fully exited Blueprint Medicines in Q3 2020, selling an estimated $15.7M.
  • Ikarian Capital's ten largest holdings make up 41% of its $1.38B portfolio in Q3 2020.
  • Ikarian Capital opened 73 new positions and closed 63 in Q3 2020.
  • Ikarian Capital's portfolio value rose 10% quarter-over-quarter to $1.38B.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.